Although BAT is in the early stages of its transition, last year's volume growth rates were promising for vapor (+52%), modern oral (+62%), and heated tobacco (+19%) following an equally strong 2019
As I was saying, there are directors who come back, but we usually have a different director for every episode, so sometimes Im working with new people and some days are more stacked than others
These include NtZIP1-like, NtZIP4, NtZIP11-like, NtNRAMP3-like, NtMTP2-X1/X2 , NtMRP10-like and NtMRP14-like (from the Multidrug Resistance-Associated Proteins Family) (Papierniak et al
nicotine pouches come in 2 mg, 4 mg, and 8 mg strengths
But the adult vaper market clearly wants this potential on tap, making this a coin flip
Do you have a similar (or different) perspective